Return to Diabetes Health
September 27, 2006
Actos Prevents Recurrent Heart Attacks
A new study has shown that diabetes drug Actos (pioglitazone) reduces the risk of recurrent heart attack in diabetics by 28 percent. While many were excited by the news, others were more cautious.
"This should draw attention to the use of pioglitazone, and it should get serious consideration, but it's a first, so it needs validation," said Dr. Robert H. Eckel, president of the American Heart Association. "One study should not make a paradigm for management."